<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: SEPTEMBER 24, 1998
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. announced that Daniel Tosteson, M.D., the
retired dean of Harvard Medical School, joined the Photogen Scientific
Advisory Council, as more fully described in the Company's Press
Release dated September 24, 1998 filed as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated September 24, 1998, announcing
that Daniel Tosteson, M.D.,the retired dean of Harvard Medical School,
joined the Photogen Scientific Advisory Council.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
Date: October 2, 1998 John Smolik, President
-1-
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
No. Description
- ---- -----------
<S> <C>
99 Press release of the Company, dated September 24, 1998,
announcing that Daniel Tosteson, M.D., the retired dean of
Harvard Medical School, joined the Photogen Scientific
Advisory Council
</TABLE>
-2-
<PAGE>
EXHIBIT 99
Photogen Technologies, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931
Voice: 423-769-4012
Fax: 423-769-4013
Internet: www.photogen.com
Retired Dean of Harvard Medical School Joins Photogen Scientific
Advisory Council
KNOXVILLE, Tenn.-- Sept. 24, 1998--Daniel Tosteson, M.D., retired Dean of
Harvard Medical school and an accomplished contributor to the fields of
molecular biology and medical education has joined the newly organized
Scientific Advisory Council of Photogen Technologies, Inc.
The Council was organized to provide scientific advice and counsel to the Board
of Directors and Company management team. It is charged with providing guidance
and recommendations to help the company:
- -- pursue commercially important applications,
- -- benefit from the latest developments in chemistry, biochemistry, laser
design & photochemistry,
- -- avoid investing Company resources in unprofitable areas,
- -- benefit fully from the Company's proprietary technologies,
- -- become properly staffed and equipped, and
- -- advance its interests by facilitating the development of licenses and
collaborative agreements.
From 1977 until 1997, Tosteson was the dean of the Faculty of Medicine at
Harvard University and the president of Harvard Medical Center. In addition to
his service on the editorial boards of the Journals General Physiology and
Membrane Biology, he served on the advisory boards to the Pew Scholars Program.
Tosteson has served on the Molecular Biology Panel of the National Science
Foundation and the Scientific Review Committee of the National Institutes of
Health. His career research interests are directed towards understanding the
cellular functions and molecular mechanisms of ion transport across membranes.
He has more than 160 scholarly publications to his credit, and holds honorary
degrees from New York University, Johns Hopkins, Duke and Emory.
"Photogen's team has achieved impressive results in a short period of time,"
said Tosteson. "When I was offered the chance to serve as charter member of the
Advisory Council, I thought about all of the potential applications of the
Company's technology and realized that exciting things likely were going to
happen here. I welcome the opportunity to be a part of that."
Eventually, the Company plans three to five members for the Council, which will
meet three or more times per year. Additional members will be added as
<PAGE>
qualified individuals are identified. It has no decision-making authority
within the Company, and all outside members will serve as consultants to the
Company and will be shielded from material, nonpublic information. Chairing
the committee will be the Company's vice president of research and
development, when named. In the interim, Company CEO John Smolik will serve
as chairperson.
"We believe that this Advisory Council can open to our Company a valuable source
of medical knowledge that should help us make the most of our technologies and
bring them to market more quickly," said Smolik. "Of course, our ability to
capitalize on the value brought by their recommendations is dependent upon the
success of our research and testing efforts and our ability to forge appropriate
collaborative agreements."
Photogen's scientists are working toward the development of its proprietary
multi-photon excitation technology to enhance the safety and efficacy of
photodynamic therapy for the diagnosis and treatment of cancer, infectious
diseases and other medical conditions.
Photogen Technologies, Inc., through its wholly owned subsidiary -- Photogen,
Inc. -- is a development-stage Company focused on creating photodynamic-related
health care products based on its proprietary multi-photon excitation and
related technology. The Company has discovered new methods for using
laser-generated light to activate photoactive agents within deep tissue
sufficient to produce a range of beneficial therapeutic and diagnostic outcomes.
These technologies involve methods, materials and devices that may be used to
produce light and photoactive agents that will destroy diseased cells, remove
tissue or identify and diagnose disease.
This news release may contain forward-looking statements that involve risks and
uncertainties. The company has no products or operating revenues at this time. A
full discussion of the Company's operations and financial condition, including
risk factors that may affect the Company's business and future prospects, is
contained in documents the company files with the Securities and Exchange
Commission, such as the Company's reports on Form 10-QSB, Form 10-KSB and Form
8-K. These documents identify important factors that could cause the Company's
actual performance to differ from current expectations. The common stock of
Photogen Technologies, Inc. is traded on the over-the-counter bulletin board
market under the symbol PHGN.
For information, contact Robert Cathey at Ackermann Public Relations &
Marketing, 423/584-0550, e-mail: [email protected]. Or, visit our World
Wide Web site, at www.photogen.com.
Contact:
Ackermann Public Relations & Marketing, Knoxville
Robert Cathey, 423/584-0550
or [email protected]
